Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in Vivo

International Journal of Molecular Sciences

Volumn 12, Issue 1, 2011, Pages 668-681

  Li, Wei ^a   Wang, Jie ^a   Jiang, Hong Ru ^a   Xu, Xiao Li ^a   Zhang, Jun ^a   Liu, Mei Lin ^a   Zhai, Ling Yun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell proliferation; Cyclooxygenase selective inhibitor; Mice; Ovarian carcinoma

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DRUG SCREENING; METABOLISM; OVARIAN NEOPLASMS;

ANIMALIA; MUS;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS; PYRAZOLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79251620497     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12010668     Document Type: Article

References (41)

1. Ozols, R.F. Recurrent ovarian cancer: evidence-based treatment. J. Clin. Oncol. 2002, 20, 1161-1163.
2. Dannenberg, A.J.; Subbaramaiah, K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003, 4, 431-436.
3. Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1, 11-21.
4. Smith, W.L.; Garavito, R.M.; DeWitt, D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996, 271, 33157-33160.
5. Li, J.Y.; Wang, X.Z.; Chen, F.L.; Yu, J.P.; Luo, H.S. Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J. Gastroenterol. 2003, 9, 915-920.
6. Li, W.; Zhang, H.H.; Xu, R.J.; Zhuo, G.C.; Hu, Y.Q.; Li, J. Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo. Med. Oncol. 2008, 25, 172-177.
7. Vane, J.R.; Bakhle, Y.S.; Botting, R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 97-120.
8. Half, E.; Tang, X.M.; Gwyn, K.; Sahin, A.; Wathen, K.; Sinicrope, F.A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002, 62, 1676-1681.
9. Quidville, V.; Segond, N.; Tebbi, A.; Cohen, R.; Jullienne, A.; Lepoivre, M.; Lausson, S. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid 2009, 19, 613-621.
10. Denkert, C.; Köbel, M.; Pest, S.; Koch, I.; Berger, S.; Schwabe, M.; Siegert, A.; Reles, A.; Klosterhalfen, B.; Hauptmann, S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 2002, 160, 893-903.
11. Erkinheimo, T.L.; Lassus, H.; Finne, P.; van Rees, B.P.; Leminen, A.; Ylikorkala, O.; Haglund, C.; Butzow, R.; Ristimäki, A. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin. Cancer Res. 2004, 10, 538-545.
12. Ferrandina, G.; Lauriola, L.; Zannoni, G.F.; Fagotti, A.; Fanfani, F.; Legge, F.; Maggiano, N.; Gessi, M.; Mancuso, S.; Ranelletti, F.O.; Scambia, G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann. Oncol. 2002, 13, 1205-1211.
13. Fukutake, M.; Nakatsugi, S.; Isoi, T.; Takahashi, M.; Ohta, T.; Mamiya, S.; Taniguchi, Y.; Sato, H.; Fukuda, K.; Sugimura, T.; Wakabayashi, K. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998, 19, 1939-1942.
14. Kawamori, T.; Rao, C.V.; Seibert, K.; Reddy, B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58, 409-412.
15. Daikoku, T.; Wang, D.; Tranguch, S.; Morrow, J.D.; Orsulic, S.; DuBois, R.N.; Dey, S.K. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 2005, 65, 3735-3744.
16. Gupta, R.A.; Tejada, L.V.; Tong, B.J.; Das, S.K.; Morrow, J.D.; Dey, S.K.; DuBois, R.N. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003, 63, 906-911.
17. Cramer, D.W.; Harlow, B.L.; Titus-Ernstoff, L.; Bohlke, K.; Welch, W.R.; Greenberg, E.R. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998, 351, 104-107.
18. Harris, R.E.; Kasbari, S.; Farrar, W.B. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol. Rep. 1999, 6, 71-73.
19. Reese, J.; Zhao, X.; Ma, W.G.; Brown, N.; Maziasz, T.J.; Dey, S.K. Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology 2001, 142, 3198-3206.
20. Li, W.; Xu, R.J.; Lin, Z.Y.; Zhuo, G.C.; Zhang, H.H. Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor. Med. Oncol. 2009, 26, 170-177.
21. Rao, C.V.; Indranie, C.; Simi, B.; Manning, P.T.; Connor, J.R.; Reddy, B.S. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 2002, 62, 165-170.
22. Zhao, S.; Cai, J.; Bian, H.; Gui, L.; Zhao, F. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer Invest. 2009, 27, 636-640.
23. Kundu, N.; Fulton, A.M. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 2002, 62, 2343-2346.
24. Daikoku, T.; Tranguch, S.; Trofimova, I.N.; Dinulescu, D.M.; Jacks, T.; Nikitin, A.Y.; Connolly, D.C.; Dey, S.K. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 2006, 66, 2527-2531.
25. Yao, M.; Zhou, W.; Sangha, S.; Albert, A.; Chang, A.J.; Liu, T.C.; Wolfe, M.M. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin. Cancer Res. 2005, 11, 1618-1628.
26. Li, S.; Miner, K.; Fannin, R.; Carl, B.J.; Davis, B.J. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol. Oncol. 2004, 92, 622-627.
27. Leahy, K.M.; Ornberg, R.L.; Wang, Y.; Zweifel, B.S.; Koki, A.T.; Masferrer, J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002, 62, 625-631.
28. Bottone, F.G., Jr.; Martinez, J.M.; Alston-Mills, B.; Eling, T.E. Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 2004, 25, 349-357.
29. Grosch, S.; Tegeder, I.; Niederberger, E.; Bräutigam, L.; Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15, 2742-2744.
30. Zhu, J.; Song, X.; Lin, H.P.; Young, D.C.; Yan, S.; Marquez, V.E.; Chen, C.S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl. Cancer Inst. 2002, 94, 1745-1757.
31. Kirtikara, K.; Morham, S.G.; Raghow, R.; Laulederkind, S.J.; Kanekura, T.; Goorha, S.; Ballou, L.R. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J. Exp. Med. 1998, 187, 517-523.
32. Hales, D.B.; Zhuge, Y.; Lagman, J.A.; Ansenberger, K.; Mahon, C.; Barua, A.; Luborsky, J.L.; Bahr, J.M. Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus). Endocrine 2008, 33, 235-244.
33. Urick, M.E.; Johnson, P.A. Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer. Gynecol. Oncol. 2006, 103, 673-678.
34. Li, W.; Ji, Z.L.; Zhuo, G.C.; Xu, R.J.; Wang, J.; Jiang, H.R. Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice. Med. Oncol. 2010, 27, 98-104.
35. Dore, M.; Cote, L.C.; Mitchell, A.; Sirois, J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J. Histochem. Cytochem. 1998, 46, 77-84.
36. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705-716.
37. Narko, K.; Ristimäki, A.; MacPhee, M.; Smith, E.; Haudenschild, C.C.; Hla, T. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J. Biol. Chem. 1997, 272, 21455-21460.
38. Williams, C.S.; Watson, A.J.; Sheng, H.; Helou, R.; Shao, J.; DuBois, R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000, 60, 6045-6051.
39. Gerdes, J.; Lemke, H.; Baisch, H.; Wacker, H.H.; Schwab, U.; Stein, H. Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984, 133, 1710-1715.
40. Del Vecchio, M.T.; Leoncini, L.; Buerki, K.; Kraft, R.; Megha, T.; Barbini, P.; Tosi, P.; Cottier, H. Diffuse controcytic and/or centroblastic malignant non-Hodgkins lymphomas: comparison of mitotic and pyknotic (apoptotic) indices. Int. J. Cancer 1991, 47, 38-43.
41. Kitamura, T.; Itoh, M.; Noda, T.; Matsuura, M.; Wakabayashi, K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int. J. Cancer 2004, 109, 576-580.